Shiyue Daotian (09676) reports a profit increase, with the expected adjusted annual net profit not less than 341 million yuan, a year-on-year growth of at least 110%.
In October Rice Fields (09676) released a notice, expecting the group to achieve adjusted results by the end of the fiscal year ending December 31, 2024...
SHIYUE DAOTIAN (09676) announced that it is expected to achieve adjusted net profit (measured by non-International Financial Reporting Standards) of no less than RMB 341 million for the year ending December 31, 2024, representing a growth of at least 110% compared to the same period in 2023 where adjusted net profit was RMB 162 million. The main reason for this growth in adjusted net profit is the continuous innovation and deep operation in the kitchen staple food category by the group, further optimization of product structure, strategic layout of sales channels, and significantly improved profit quality.
The company will continue to closely monitor changes in industry trends, adjust its business strategy to fully leverage its own characteristics and advantages, enhance brand influence and competitiveness, meet the needs of a wide range of consumers, and contribute to rural revitalization with practical actions. Even in the face of any challenges, the company will remain steadfast in its commitment to its mission, dedicated to providing Chinese consumers with healthy, high-quality, and safe kitchen food, and driving sustainable growth for the enterprise in the long term.
Related Articles

PetroChina's controlling shareholder and its subsidiaries have cumulatively increased their holdings in the company by 0.17%.

Gan & Lee Pharmaceuticals subsidiary obtains registration approval for sitagliptin metformin tablets (II) drug.

Estun Automation (002747.SZ): The company's H shares have been included in the list of securities eligible for trading under the Hong Kong Stock Connect.
PetroChina's controlling shareholder and its subsidiaries have cumulatively increased their holdings in the company by 0.17%.

Gan & Lee Pharmaceuticals subsidiary obtains registration approval for sitagliptin metformin tablets (II) drug.

Estun Automation (002747.SZ): The company's H shares have been included in the list of securities eligible for trading under the Hong Kong Stock Connect.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


